West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.45-3.55 for the period, compared to the Thomson Reuters consensus estimate of $3.46. The company issued revenue guidance of $1.95-1.97 billion, compared to the consensus revenue estimate of $1.95 billion.West Pharmaceutical Services also updated its FY20 guidance to $3.45-3.55 EPS.
Shares of West Pharmaceutical Services stock traded up $0.19 during trading hours on Friday, hitting $174.57. The company’s stock had a trading volume of 391,947 shares, compared to its average volume of 418,727. The business has a 50 day moving average price of $156.35 and a two-hundred day moving average price of $147.47. West Pharmaceutical Services has a 12-month low of $100.93 and a 12-month high of $175.21. The company has a market cap of $11.84 billion, a PE ratio of 57.24, a PEG ratio of 3.31 and a beta of 1.21. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.31 and a current ratio of 3.00.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.10. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. The business had revenue of $470.60 million for the quarter, compared to the consensus estimate of $451.53 million. During the same period in the previous year, the business earned $0.73 earnings per share. The business’s revenue was up 11.4% on a year-over-year basis. As a group, research analysts anticipate that West Pharmaceutical Services will post 3.14 earnings per share for the current year.
WST has been the topic of several research reports. Bank of America cut West Pharmaceutical Services from a neutral rating to an underperform rating and set a $135.00 target price on the stock. in a report on Thursday, December 12th. Zacks Investment Research cut West Pharmaceutical Services from a buy rating to a hold rating in a report on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $132.29.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: What are no-load funds?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.